Could a new drug help heart failure patients breathe easier and think sharper?
NCT ID NCT07202000
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 26 times
Summary
This study tests whether an investigational drug (activin ligand-trap) combined with exercise training can improve exercise capacity and thinking skills in people with a type of heart failure called HFpEF. About 48 adults aged 40 and older with obesity will receive either the drug or a placebo for 12 weeks. The goal is to see if the drug helps them use oxygen better during exercise and boosts cognitive function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.